Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pasireotide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    43 result(s) found for: Pasireotide. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2013-000267-84 Sponsor Protocol Number: CSOM230B2412 Start Date*: 2013-06-07
    Sponsor Name:NOVARTIS FARMA
    Full Title: An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continue...
    Medical condition: Cushing’s disease Neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10062476 Neuroendocrine tumor LLT
    14.1 10014698 - Endocrine disorders 10011652 Cushing's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed) ES (Completed) GR (Completed) FR (Completed) PL (Completed) PT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-014457-33 Sponsor Protocol Number: STH 15164 Start Date*: 2010-10-18
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: An Open Label, Longitudinal Study of the Effects of Subcutaneous Acute and Chronic Pasireotide (SOM230) Therapy on Adrenocorticotrophic Hormone and Tumour Volume in Patients with Nelson's Syndrome.
    Medical condition: Nelson's Syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002170-49 Sponsor Protocol Number: CSOM230B2411 Start Date*: 2013-11-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing's disease
    Medical condition: Cushing's disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004860 10011651 Cushing's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Completed) ES (Prematurely Ended) BE (Prematurely Ended) HU (Prematurely Ended) GR (Completed) NL (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002916-16 Sponsor Protocol Number: CSOM230B2219 Start Date*: 2014-08-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, open-label, Phase IV study to investigate the management of pasireotide-induced hyperglycemia with incretin based therapy or insulin in adult patients with Cushing’s ...
    Medical condition: Cushing's disease and acromegaly
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004860 10011651 Cushing's disease LLT
    19.0 100000004860 10000600 Acromegaly and gigantism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) PL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002219-41 Sponsor Protocol Number: NL49517 Start Date*: 2015-07-22
    Sponsor Name:Erasmus Medical Centre
    Full Title: A prospective single-centre double blind randomized study on the efficacy and safety of 4 weekly pasireotide LAR administration in combination with or without weekly pegvisomant in previously contr...
    Medical condition: Acromegaly
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007348-32 Sponsor Protocol Number: CSOM230D2203 Start Date*: 2009-05-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin
    Medical condition: The following tumors are included: 1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma, 2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Pr...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-002630-31 Sponsor Protocol Number: CSOM230C2413 Start Date*: 2015-03-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase IIIb multicenter, open-label, single arm study to evaluate the efficacy and safety of pasireotide in patients with acromegaly inadequately controlled with first generation somatostatin ana...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    19.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) PT (Completed) IT (Completed) FR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-000700-84 Sponsor Protocol Number: pasireotide01 Start Date*: 2008-07-28
    Sponsor Name:UZ Leuven
    Full Title: A single center trial with a randomized, double-blind, placebo-controlled phase to assess safety and efficacy of sc pasireotide in patients with dumping syndrome, followed by an open label phase on...
    Medical condition: dumping syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013810 Dumping syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001534-34 Sponsor Protocol Number: CSOM230X2203 Start Date*: 2012-09-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, intra-patient dose escalation phase II study to evaluate the preliminary efficacy, safety and pharmacokinetics of pasireotide (SOM230) subcutaneous (s.c.) followed by pasireotide LA...
    Medical condition: adult patients with dumping syndrome age 18 years or greater, male and female, with having a history of documented diagnosis of dumping syndrome defined as having a history of/or active symptoms as...
    Disease: Version SOC Term Classification Code Term Level
    17.1 10022117 - Injury, poisoning and procedural complications 10013810 Dumping syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-004707-67 Sponsor Protocol Number: 2014-880 Start Date*: 2016-01-13
    Sponsor Name:Hospices Civils de Lyon
    Full Title: REDUCTION BY PASIREOTIDE OF THE EFFLUENT VOLUME IN HIGH-OUTPUT ENTEROSTOMY IN PATIENTS REFRACTORY TO USUAL MEDICAL TREATMENT: PHASE II MULTICENTRIC RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY
    Medical condition: Patients with high-output ileostomy or jejunostomy and failure of treatment with loperamide +/- codein syrup
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10021321 Ileostomy PT
    18.1 10042613 - Surgical and medical procedures 10023180 Jejunostomy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000739-25 Sponsor Protocol Number: CSOM230C2303 Start Date*: 2008-01-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, blinded efficacy and safety study of pasireotide LAR vs octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately contr...
    Medical condition: Metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by somatostatin analogues
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007271 Carcinoid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FR (Completed) DE (Completed) IT (Prematurely Ended) ES (Prematurely Ended) GB (Completed) BE (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000212-16 Sponsor Protocol Number: HYKS-190116 Start Date*: 2016-04-12
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Hydrocortisone vs. pasireotide in preventing pancreatic fistula and other complications after pancreatic resection - a prospective, randomized, controlled trial
    Medical condition: Patients undergoing pancreatic resection.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2010-023183-40 Sponsor Protocol Number: CSOM230I2201 Start Date*: 2011-06-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open-label phase II multicenter study evaluating the efficacy of oral Everolimus alone or in combination with Pasireotide LAR i.m. in advanced progressive pancreatic neuroendocrine tu...
    Medical condition: advanced progressive pancreatic neuroendocrine tumors (PNET)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067517 Pancreatic neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Completed) HU (Completed) ES (Completed) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002872-17 Sponsor Protocol Number: CSOM230DIC03 Start Date*: 2013-06-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Multicenter 3-arm trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and th...
    Medical condition: Neouroendocrine carcinoma of the lung and thymus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025064 Lung carcinoma LLT
    20.0 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Prematurely Ended) SE (Prematurely Ended) ES (Completed) FR (Prematurely Ended) NL (Prematurely Ended) DK (Completed) DE (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001067-23 Sponsor Protocol Number: PasHypo Start Date*: 2018-05-07
    Sponsor Name:Zealand University Hospital
    Full Title: Pasireotide in the treatment of hypoglycemia following gastric bypass surgery
    Medical condition: Postprandial reactive hypoglycemia in patients with prior Roux-en-Y gastric bypass surgery.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10059038 Postprandial hypoglycemia LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-006824-20 Sponsor Protocol Number: CSOM230BDE02 Start Date*: 2007-11-08
    Sponsor Name:Universitätsklinikum Essen - Zentrum für Innere Medizin - Klinik für Endokrinologie
    Full Title: Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Pheochromocytoma – proof of concept study
    Medical condition: Pheochromocytoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034876 Pheochromocytoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-021008-77 Sponsor Protocol Number: PASIREOTIDE/01/2010 Start Date*: 2011-08-22
    Sponsor Name:Göteborgs Universitet, Göteborg Sweden
    Full Title: A MULTI - CENTER OPEN LABEL PHASE II (B) STUDY TO ASSESS EFFECTS OF SOM230 ON CARDIOVASCULAR PARAMETERS IN ACROMEGALIC PATIENTS
    Medical condition: Adult patients 18 to 80 years of age with diagnosed acromegaly eligible for treatment with a somatostatin analogue and not on previous pharmacological treatment for acromegaly.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004111-22 Sponsor Protocol Number: CSOM230B2305 Start Date*: 2007-01-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recu...
    Medical condition: Cushing’s disease is rare disease that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. The elevated ACTH secreted by these tumors stimulates the adrenal glands to pr...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011651 Cushing's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) BE (Completed) IT (Completed) FI (Completed) FR (Completed) DE (Completed) PT (Completed) GR (Completed) GB (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-001972-36 Sponsor Protocol Number: CSOM230C2305 Start Date*: 2007-11-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, blinded study to assess the safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegaly.
    Medical condition: Acromegaly is characterized by chronic hypersecretion of growth hormone (GH), clinical features comprise structural and functional changes occurring in practically all organs. Cardiovascular diseas...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) BE (Completed) GB (Completed) GR (Completed) IT (Completed) ES (Completed) NL (Completed) DK (Completed) SE (Completed) HU (Completed) PL (Completed) PT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002507-18 Sponsor Protocol Number: CSET2019/2955 Start Date*: 2020-04-10
    Sponsor Name:Gustave Roussy
    Full Title: Efficacy and feasibility of pasireotide to reduce clinically relevant digestive leakage after complete cytoreductive surgery (CRS) plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for perito...
    Medical condition: Primary and secondary peritoneal malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10068069 Peritoneal carcinomatosis LLT
    20.1 10022891 - Investigations 10080244 Peritoneal cancer index PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 07:25:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA